AU Patent

AU2012327170A1 — Therapeutic compounds

Assigned to Gilead Sciences Inc · Expires 2013-08-22 · 13y expired

What this patent protects

The use of {9-[(R)-2-[[(S)-i[(S)-I (isopropoxvcarbonyl)etil]amino]phenoxvphosphinyl] -rnethoxy ]propyl ]adenine } and the henifinarate form (tenofovir alafenamide hemifumarate) in combination with cobicistat is disclosed. In addition, the combination of tenofovir alafenamide heni…

USPTO Abstract

The use of {9-[(R)-2-[[(S)-i[(S)-I (isopropoxvcarbonyl)etil]amino]phenoxvphosphinyl] -rnethoxy ]propyl ]adenine } and the henifinarate form (tenofovir alafenamide hemifumarate) in combination with cobicistat is disclosed. In addition, the combination of tenofovir alafenamide heniifumarate, cobicistat, emtricitabine, and elvitegravir is disclosed.

Drugs covered by this patent

Patent Metadata

Patent number
AU2012327170A1
Jurisdiction
AU
Classification
—
Expires
2013-08-22
Drug substance claim
No
Drug product claim
No
Assignee
Gilead Sciences Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.